WCN26-5205 REAL-WORLD ANEMIA MANAGEMENT BEFORE HEMODIALYSIS INITIATION IN JAPAN: A RETROSPECTIVE MULTICENTER COHORT STUDY

20260 citationsJournal Articlegold Open Access

Authors

Hideka Miyauchi · Kyoto Prefectural University of Medicine

Yu Mihara · Kyoto Prefectural University of Medicine

Minato Umehara · Kyoto Prefectural University of Medicine

Kunihiro Nakai · Japanese Red Cross Society Kyoto Daini Hospital

Hozue Ehara · Matsushita Memorial Hospital

Tomoharu Ida

Yayoi Shiotsu · Japanese Red Cross Society Kyoto Daini Hospital

Abstract

Anemia is a common complication of chronic kidney disease (CKD) and contributes to the progression of both CKD and heart failure. Although current guidelines recommend maintaining hemoglobin (Hb) within the target range, Hb levels often decline progressively under uremic conditions in advanced CKD. In Japan, five hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) have been approved since 2021, expanding therapeutic options for anemia management. HIF-PHIs are expected to enhance iron utilization and may be effective in patients with hyporesponsiveness to erythropoiesis-stimulating agents (ESAs).

Topics & Keywords

Erythropoietin and Anemia Treatment Dialysis and Renal Disease Management Blood transfusion and management

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Kidney International Reports

Volume 11, Issue 4, pp. 104235-104235

DOI: 10.1016/j.ekir.2026.104235

Field-Weighted Citation Impact: 0.00